Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case–control study

Abstract

Objective This study was to determine and compare the prevalences of polypharmacy and comorbidities in patients aged 50 years or older with those patients younger than 50 years in a Mexican population. Results One hundred and twenty-five patients were enrolled, 60 (48%) were aged 50 years or older. The median CD4+ cell counts were 509 cells/μL (interquartile range [IQR]: 324–730) for the older patients and 384 cells/μL (IQR: 262–562) ( P = 0.021) for the younger patients. Viral suppression were significantly higher in the older group: 80% vs. 63% ( P = 0.037). The number of comorbidities was significantly higher in the older group, with a median of 2 (IQR: 2–3) vs. 1 (IQR: 0–1) ( P ≤ 0.001). After adjustment of the logistic regression model in the older group, the following comorbidities differed between the age groups: systemic arterial hypertension (odds ratio [OR]: 15.75; 95% confidence interval [CI] 3.49–71.05; P = < 0.001), diabetes mellitus (OR: 14.36; 95% CI 1.79–115.07; P = 0.001), osteoarthritis (OR: 10.33; 95% CI 2.88–37.05; P = < 0.001), hyperlipidemia (OR: 2.78; 95% CI 1.22–6.34; P = 0.001), and polypharmacy (OR: 6.58; 95% CI 3.01–14.39; P = 0.001).

Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis

“…The reasons for exclusion are laid out in Figure 1 . Thereafter, 35 potentially relevant studies were selected for full text review, of which 23 21 , 36 – 57 studies satisfied the inclusion for the network meta-analysis. The source of data for the selected studies ranged from HIV outpatient clinics and University/Tertiary hospital pharmacies to multicentre AIDS cohort studies ( Table 1 ).…”

What is Polypharmacy In People Living With HIV/AIDS? A Systematic Review

“…There was a total of 36 de nitions of polypharmacy, with studies further divided based on the magnitude of polypharmacy (Table 1); minor polypharmacy (N = 3); major polypharmacy (N = 29); "severe" polypharmacy (N = 2); "excessive" polypharmacy (N = 1); "higher" polypharmacy (N = 1) (Table 2). Major 29 [2], [6], [8], [15], [17][18][19][20][21][22][23][24][25][26][27][28][29], [31][32][33][34][35][36][37][38][39][40] Severe 2 [23] [26] [39] Excessive 1 [11] Higher 1 [39] Duration of Polypharmacy Amongst the included studies, 16% (N = 5) incorporated the duration of treatment to the de nition of polypharmacy, while a signi cant proportion 84% (N = 26) only provided the numerical de nition of polypharmacy with no additional information on its duration. Gimeno-Gracia et al further strati ed drug exposure based on the following duration: greater than 1 day; greater than 90 days; and greater than 180 days [14,36].…”

Musculoskeletal Conditions in Persons Living with HIV/AIDS: A Scoping Review

“…Eleven studies from the USA [22, 23, 26, 28, 31-34, 36, 37, 41] , three from Nigeria [25,38,39] , three from France [12,29,40] and one each from Denmark [24] , South Africa [27] , Germany [42] , India [30] , Ethiopia [43] , Canada [35] , Malawi [44] , Mexico [45] , Uganda [46] , and the United Kingdom and Zambia [47] were included. All studies were published in English.…”

“…Three studies reported that some patients were receiving ART [37,40,42] . Two studies reported ART use [26,45] but did not specify the percentage of participants on ART. Five studies did not report on ART [12,22,23,25,27] , while seventeen studies reported the percentages of patients receiving ART ranging from 50-100% [24, 28-36, 38, 39, 41, 43, 44, 46, 47] .…”